from the pseudoscience dept.
In 2016, Homeopathy lost its slot on Thomson Reuters’s (now Clarivate’s) influential journal rankings list after an analysis found that more than 70% of citations in the papers it published were of papers it published. That led Elsevier to cut the journal loose — although it remains in business under the umbrella of Thieme, and has since earned its impact factor back.
Part of Homeopathy’s mission under new ownership, it seems, is to criticize journals that have spurned its contributors. Well, one journal, anyway.
Last November, the journal published a commentary by two researchers of Verona. The piece objected to the retraction earlier in the year of a paper on homeopathy and wound healing by one of the authors, Marta Marzatto — who didn’t agree with the decision then and hasn’t gotten over the slight [...]
In June 2019, the journal PLoS ONE retracted an original research article, published in 2016, which described the effects of homeopathic Arnica montana on interleukin-4 treated human macrophages. The results showed an increase in extracellular matrix gene expression, including the gene encoding fibronectin, which is one of the main proteins involved in connective tissue healing. Here, the authors of the article discuss the critical points raised by the journal in the retraction note, with a focus on the specific methodological aspects of research on high dilutions of natural compounds. The editorial arguments made to justify the retraction did not prove any methodological errors, nor scientific misconduct. As a general rule, when a study published by a group of researchers raises scientific doubts because the results appear at variation with the commonly accepted knowledge in a field, the study is repeated by other scholars and any contrasting results are published and/or discussed. Therefore, retraction of the Arnica m. study by PLoS ONE is a violation of the conventions of scientific publication and knowledge-sharing methods derived from honest experimental method.
And earlier this month, the journal took another shot at PLoS ONE. In this case, the authors, a group from Mexico City, tried the old "like cures like" approach:
In April 2020 PLoS ONE retracted an original clinical research article, published in 2015, in which we demonstrated that individualized homeopathic treatment improves depression symptoms in climacteric women. The original assessment of this study was carried out by an expert in psychiatry (depression research) with close to 35 years’ experience in the field of mental health. During post-publication discussions, no serious breaches of scientific procedure or misconduct were even insinuated. Our team answered all “points of concern”, raised by the current PLoS ONE editors, in extensive detail. All these were potential limitations of our study, which would usually be addressed by one of several appropriate post-publication actions, ranging from discussion of the concern within a systematic review, through to correcting the study itself by adding a correction notice. Therefore, in the interests of transparency and accuracy, a summary of the most relevant points is provided, so that a fair-minded reader can objectively form a clear opinion.